Adicet Bio, Inc. (ACET)
Stock Price:
$12.53 USD
-0.33 (-2.57%)
Updated Oct 23, 2020 3:25 PM EDT - Market open
Key Info
| Market Cap |
245.46M |
| Revenue (ttm) |
4.39M |
| Net Income (ttm) |
-65.98M |
| Shares Out |
19.59M |
| EPS (ttm) |
-1.97 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$12.53 |
| Previous Close |
$12.86 |
| Change ($) |
-0.33 |
| Change (%) |
-2.57% |
| Day's Open |
13.00 |
| Day's Range |
12.15 - 13.37 |
| Day's Volume |
68,363 |
| 52-Week Range |
6.02 - 69.16 |
More Stats
| Market Cap |
245.46M |
| Enterprise Value |
174.33M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
19.59M |
| Float |
17.27M |
| EPS (basic) |
-13.44 |
| EPS (diluted) |
-1.97 |
| FCF / Share |
-13.04 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
134,556 |
| Short Ratio |
0.33 |
| Short % of Float |
0.78% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
55.95 |
| PB Ratio |
3.47 |
| Revenue |
4.39M |
| Operating Income |
-67.63M |
| Net Income |
-65.98M |
| Free Cash Flow |
-67.90M |
| Net Cash |
71.13M |
| Net Cash / Share |
3.63 |
| Gross Margin |
22.68% |
| Operating Margin |
-1,541.58% |
| Profit Margin |
n/a |
| FCF Margin |
-1,547.82% |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
-179.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$14.50*
(15.72% upside)
Low
4.00
Current: $12.53
High
25.00
Target: 14.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -85.46 | -39.71 | -18.88 |
| Net Income | -82.74 | -37.61 | -33.78 |
| Shares Outstanding | 4.90 | 3.78 | 0.57 |
| Earnings Per Share | -16.87 | -9.94 | -58.94 |
| Operating Cash Flow | -73.68 | -35.45 | -10.99 |
| Capital Expenditures | -0.27 | -0.36 | -0.04 |
| Free Cash Flow | -73.95 | -35.81 | -11.03 |
| Cash & Equivalents | 91.72 | 108 | 53.35 |
| Net Cash / Debt | 91.72 | 108 | 53.35 |
| Assets | 93.91 | 110 | 55.19 |
| Liabilities | 12.21 | 5.74 | 5.50 |
| Book Value | 81.70 | 104 | -31.93 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Adicet Bio, Inc. |
| Country |
United States |
| Employees |
69 |
| CEO |
Chen Schor |
Stock Information
| Ticker Symbol |
ACET |
| Stock Exchange |
NASDAQ |
| Sector |
Health Technology |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ACET |
Description
Adicet Bio, a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors or T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Its products pipeline includes ADI-001, which is in Phase 1 clinical study to treat non-Hodgkin's lymphoma; and ADI-002 that is in Phase 1 clinical study for the treatment of hepatocellular carcinoma and other solid tumors. The company is based in Menlo Park, California.